Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

Neuro-Oncology

Volumn 13, Issue 12, 2011, Pages 1331-1338

  Butowski, Nicholas ^a   Chang, Susan M ^a   Lamborn, Kathleen R ^a   Polley, Mei Yin ^a   Pieper, Russell ^a   Costello, Joseph F ^a   Vandenberg, Scott ^a   Parvataneni, Rupa ^a   Nicole, Angelina ^a   Sneed, Patricia K ^a   Clarke, Jennifer ^a   Hsieh, Emily ^a   Costa, Bruno M ^b   Reis, Rui M ^b   Hristova Kazmierski, Maria ^c   Nicol, Steven J ^c   Thornton, Donald E ^c   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINHO   (Portugal)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Adjuvant therapy; Enzastaurin; Glioblastoma multiforme; Radiation therapy; Temozolomide.

Indexed keywords

6 O CYCLOHEXYLMETHYLGUANINE; DNA METHYLTRANSFERASE; ENZASTAURIN; ERLOTINIB; MOLECULAR MARKER; RETINOIC ACID; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DRUG EFFECT; DRUG WITHDRAWAL; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; RADIATION DOSE; THROMBOCYTOPENIA; TOXICITY; TUMOR GROWTH; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; GLIOSARCOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863011588     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor130     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006;2:689-700. (Pubitemid 44764211)
3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol. 2007;25:4127-4136. (Pubitemid 47492957)
4. Teicher BA, Alvarez E, Mendelsohn LG, Ara G, Menon K, Ways DK. Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy. Adv Enzyme Regul. 1999;39:313-327.
5. Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs. 1999;17:227-240. (Pubitemid 30037956)
6. Donson AM, Banerjee A, Gamboni-Robertson F, Fleitz JM, Foreman NK. Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neuro-Oncol. 2000;47:9-15.
7. Chan AS, Leung SY, Wong MP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol. 1998;22:816-826. (Pubitemid 28328228)
8. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res. 2003;9:3369-3375. (Pubitemid 37082732)
9. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res. 2001;7:634-640. (Pubitemid 32707989)
10. Aeder SE, Martin PM, Soh JW, Hussaini IM. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene. 2004;23:9062-9069. (Pubitemid 40013073)
11. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C betaselective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65:7462-7469. (Pubitemid 41161281)
12. Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C beta II regulates Akt phosphorylation on Ser-473 in a cell type- and stimulusspecific fashion. J Biol Chem. 2004;279:47720-47725. (Pubitemid 39540919)
13. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2004;53:133-140. (Pubitemid 38186992)
14. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61: 153-161. (Pubitemid 46363842)
15. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24: 4092-4099. (Pubitemid 46622284)
16. Rademaker-Lakhai JM, Beerepoot LV, Mehra N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C b-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2007;13:4474-4481. (Pubitemid 47219716)
17. Welch PA, Sinha VP, Cleverly AL, Darstein C, Flanagan SD, Musib LC. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects. J Clin Pharmacol. 2007;47:1138-1151.
18. Kreisl TN, Kotliarova S, Butman JA, et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010;12:181-189.
19. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study. Neuro Oncol. 2010;12:608-613.
20. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
21. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003. (Pubitemid 40349502)
22. Millar DS, Warnecke PM, Melki JR, Clark SJ. Methylation sequencing from limiting DNA: Embryonic, fixed, and microdissected cells. Methods. 2002;27:108-113. (Pubitemid 34757120)
23. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826. (Pubitemid 26296693)
24. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797. (Pubitemid 29086728)
25. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60:5954-5958.
26. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16:2443-2449.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60: 353-357. (Pubitemid 39233451)
29. Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005;61:1454-1459. (Pubitemid 40470428)
30. Prados MD, Chang SM,Butowski N, et al. Phase II studyof erlotinibplustemozolomide during and after radiation therapy in patientswith newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579-584.